Mantomed

Memantine hydrochloride, the active ingredient in Mantomed, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adults.

GNH USA supplies Mantomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mantomed is an NMDA‑receptor antagonist used in the management of neurodegenerative disease.

Alzheimer's disease: improves cognition, daily functioning and behavioral symptoms in patients with moderate to severe disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Somnolence - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Hepatic dysfunction - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior

Safety considerations should be reviewed before initiating therapy. - Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function tests. - History of seizures: use with caution. - Elderly patients: increased risk of confusion and falls. - Concomitant NMDA antagonists: avoid combined use. - Store at below 25°C: keep in the original packaging, protect from moisture.

Potential drug‑drug interactions should be assessed.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can exacerbate CNS effects. - Strong CYP450 inhibitors (e.g., itraconazole): may raise plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive side effects. - Diuretics: monitor electrolyte balance and blood pressure. - Antihypertensives: possible additive blood pressure reduction.